Sur-Viiv-al of the Fittest: Pfizer, GSK Joint Venture Blunts Rebate Impact

The HIV joint venture Viiv is a ground breaking vision of partnership in the biopharma industry. It also turns out to be a great way to blunt the impact from health care reform on the two JV partners. There may be implications for future business development activities.